Welcome to our dedicated page for PALISADE BIO SEC filings (Ticker: PALI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Palisade Bio, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing oral PDE4 inhibitor prodrugs. Disclosures include proxy materials for annual and special stockholder meetings, director elections, auditor ratification, charter-amendment voting matters and compensation-plan governance.
Material-event reports and registration statements cover clinical-development service arrangements, common-stock sales, securities registration, capital-structure updates, Nasdaq listing compliance and meeting adjournment or withdrawal actions. The filings also provide formal context for PALI-2108 development activities, equity financing mechanics, corporate governance and public-company reporting obligations.
PALISADE BIO, INC. director Robert Baltera Jr. reported two open-market purchases of Common Stock. He bought 20,000 shares on July 8, 2026 at a weighted average price of $1.9899 per share, and 25,000 shares on July 9, 2026 at a weighted average price of $1.9560 per share. Following these transactions, he directly holds 461,904 shares. Each daily price is a weighted average of multiple trades within the stated intraday price ranges.
Palisade Bio director Robert Baltera Jr. reported open-market purchases of a total of 50,000 shares of common stock. He bought 20,000 shares on July 6, 2026 at a weighted average price of $2.052 per share and 30,000 shares on July 7, 2026 at a weighted average price of $2.0348 per share. The filing notes the trades were executed in multiple transactions within price ranges of $2.04–$2.068 and $2.00–$2.07. Following these purchases, Baltera directly owns 416,904 shares of Palisade Bio common stock.
Palisade Bio Chief Medical Officer Mitchell Lawrence Jones reported routine equity compensation activity involving restricted stock units (RSUs) and related tax sales. On July 6, he exercised 131,167 RSUs into an equal number of common shares at a stated price of $0.00 per share, reflecting settlement of vested awards granted on February 9, 2026. As part of this vesting, 51,880 common shares were sold at a weighted average price of $2.0535 per share solely to cover tax withholding obligations, with individual sale prices ranging from $2.045 to $2.06. Following these transactions, Jones directly holds 94,009 shares of common stock and 655,833 RSUs, which continue to vest with 1/6 of the RSUs scheduled to vest on July 6, 2026 and the remainder vesting quarterly over the next 10 quarters, subject to his continued service. His holdings also include 1,459 shares acquired under the company’s Employee Stock Purchase Plan on May 20, 2026.
PALISADE BIO, INC. CEO and CFO John David Finley reported routine equity compensation activity, including RSU settlement, warrant exercise, and a related share sale to cover taxes. On July 6–7, 2026, he acquired 335,167 common shares through vested Restricted Stock Units and 133 shares via exercise of a Series 2 warrant at $0.70 per share. He then sold 146,798 common shares at a weighted average price of $2.0664 per share solely to satisfy tax withholding obligations tied to the RSU vesting. After these transactions, he holds 217,688 common shares directly and 51 shares indirectly through FCW Investments, LLC, over which he has sole voting and investment power.
Palisade Bio director Robert Baltera Jr. bought a total of 30,000 shares of Palisade Bio common stock in open-market transactions, paying $1.98 per share. The purchases occurred over two days and increased his direct holdings to 366,904 shares.
The filing notes that the reported price is a weighted average, with individual trades executed between $1.97 and $1.99 per share. These transactions represent additional personal investment in the company by a board member, rather than option exercises or compensation-related grants.
Baltera Robert Jr. reported acquisition or exercise transactions in this Form 4 filing.
Palisade Bio director Robert Baltera Jr. received a grant of 336,904 Restricted Stock Units (RSUs) of common stock. Each RSU represents a right to one share and was awarded at $0.00 per share. The RSUs vest in three equal annual installments starting on June 10, 2026, contingent on his continued service, and his reported direct holdings after this grant are 336,904 shares.
PALISADE BIO, INC. director Robert Baltera Jr. has filed an initial Form 3, which is a statement of beneficial ownership for insiders. The data provided shows no reported buy, sell, exercise, gift, tax withholding, or restructuring transactions, indicating purely administrative reporting at this stage.
Palisade Bio director Binxian Wei reported equity compensation activity involving restricted stock units (RSUs) and common shares. On June 10, 2026, Wei received a grant of 592,300 RSUs of Palisade Bio common stock at no cash cost.
The filing also shows 20,200 RSUs converting into the same number of common shares as they vested on June 10, 2026. One line reports 613,355 common shares held directly after the RSU vesting, and another reports 593,155 shares after the new RSU grant. The RSU awards are subject to service-based vesting over three annual installments tied to future stockholder meetings or specified anniversaries, so Wei must remain in service for full delivery of shares.